» Articles » PMID: 37915089

Barriers and Facilitators of Implementing Electronic Monitors to Improve Adherence and Health Outcomes in Tuberculosis Patients: Protocol for a Systematic Review Based on the Consolidated Framework for Implementation Research

Overview
Publisher Biomed Central
Date 2023 Nov 2
PMID 37915089
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Tuberculosis (TB) has been regarded as 'a relentless scourge', increasing morbidity and mortality and burdening vulnerable populations. Poor adherence to TB treatment and ineffective traditional interventions hinders TB control. A novel TB approach called 'electronic monitors', equipping medication boxes with daily audio or visual reminders for electronically monitoring medication intake, seems promising in improving adherence and health outcomes and overcoming the weaknesses of traditional interventions. However, no review has systematically examined and synthesized the influencing factors of implementing electronic monitors. Implementation research offers the means to analyse the influencing factors of the implementation and its process, fitting well with the aim of this review. Therefore, the widely recognized Consolidated Framework for Implementation Research (CFIR), which offers a common taxonomy for evaluating intervention implementation, will be adopted to systematically identify barriers and facilitators of the electronic monitors for improving adherence and health outcomes in patients with TB.

Methods And Analysis: The systematic review will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Literature research will be conducted in five electronic databases (Ovid MEDLINE, CINAHL, EMBASE, Cochrane Library and Web of Science) to identify the barriers and facilitators of implementing electronic monitors in patients with TB. The CFIR will be used as a guide for categorizing and synthesizing the barriers and facilitators. Study screening, data extraction, quality appraisal and data analysis will be conducted by two independent reviewers. The use of additional reviewers will solve any disagreements between the two reviewers.

Discussion: Given the increased prominence of TB epidemiology and the adherence problem of electronic monitors, there is a solid rationale for synthesizing the existing studies via the CFIR. The findings and conclusion of this review will lay bare the achievements and effectiveness of implementing electronic monitors, as well as the attendant gaps and limitations. Further strategies for facilitating the implementation of electronic monitors will also be explored. This review will be of essential significance for research and practice, supporting future academic research initiatives centred on patients with TB and aiding electronic monitor design in lowering the morbidity and mortality associated with TB disease.

Trial Registration Number: PROSPERO: CRD42023395747.

Citing Articles

Implementation outcomes of tuberculosis digital adherence technologies: a scoping review using the RE-AIM framework.

Chilala C, Foster N, Bahukudumbi S, Mohamed M, Zary M, Kafie C BMJ Glob Health. 2025; 10(2).

PMID: 39947715 PMC: 11831268. DOI: 10.1136/bmjgh-2024-016535.


Designing community-based strategies to reach non-household contacts of people with tuberculosis in Lusaka, Zambia: a rapid qualitative study among key stakeholders.

Kerkhoff A, Foloko M, Kundu-Ngandu E, Nyirenda H, Jabbie Z, Syulikwa M Front Public Health. 2025; 12:1408213.

PMID: 39872096 PMC: 11769986. DOI: 10.3389/fpubh.2024.1408213.


Barriers and facilitators to high-volume evidence-based innovation and implementation in a large, community-based learning health system.

Durojaiye C, Prausnitz S, Schneider J, Lieu T, Schmittdiel J, Rouillard S BMC Health Serv Res. 2024; 24(1):1446.

PMID: 39574134 PMC: 11580646. DOI: 10.1186/s12913-024-11803-5.

References
1.
Acosta J, Flores P, Alarcon M, Grande-Ortiz M, Moreno-Exebio L, Puyen Z . A randomised controlled trial to evaluate a medication monitoring system for TB treatment. Int J Tuberc Lung Dis. 2021; 26(1):44-49. PMC: 8734191. DOI: 10.5588/ijtld.21.0373. View

2.
Broomhead S, Mars M . Retrospective return on investment analysis of an electronic treatment adherence device piloted in the Northern Cape Province. Telemed J E Health. 2011; 18(1):24-31. DOI: 10.1089/tmj.2011.0143. View

3.
Klein K, Bernachea M, Irribarren S, Gibbons L, Chirico C, Rubinstein F . Evaluation of a social protection policy on tuberculosis treatment outcomes: A prospective cohort study. PLoS Med. 2019; 16(4):e1002788. PMC: 6490910. DOI: 10.1371/journal.pmed.1002788. View

4.
McLaren Z, Milliken A, Meyer A, Sharp A . Does directly observed therapy improve tuberculosis treatment? More evidence is needed to guide tuberculosis policy. BMC Infect Dis. 2016; 16(1):537. PMC: 5050573. DOI: 10.1186/s12879-016-1862-y. View

5.
Park S, Sentissi I, Gil S, Park W, Oh B, Son A . Medication Event Monitoring System for Infectious Tuberculosis Treatment in Morocco: A Retrospective Cohort Study. Int J Environ Res Public Health. 2019; 16(3). PMC: 6388172. DOI: 10.3390/ijerph16030412. View